You are here:
Indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A or haemophilia B.
No estimate possible yet
Registration application pending
Marstacimab
Cardiovascular diseases
New medicine (specialité)
Other medication for cardiovascular diseases
Pfizer
Centralised (EMA)
October 2023
November 2024
No
NCT03938792
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines